Neurology® Podcast

1) Adult neurology training and 2) Topic of the month: Apraxias. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Howard Goodkin interviews Dr. Nina Schor about her paper on adult neurology training during child neurology residency. Dr. Chafic Karam is reading our e-Pearl of the week about transthyretin amyloidosis. In the next part of the podcast Dr. Ted Burns interviews Dr. Ken Heilman about dissociation and conceptual apraxia. The participants had nothing to disclose except Drs. Goodkin, Schor, Karam, Burns and Heilman.Dr. Goodkin serves on the scientific board for Tuberous Sclerosis Alliance and CURE; serves on the editorial board for Neurology and Surgical Neurology International; received royalties for an entry in Up-to-date entitled: The choking game and other strangulation activities in children and adolescents and is funded by NIH grants.Dr. Schor serves as an editorial board member for MedLink Neurology, Neurology, Pediatric Neurology and Journal of Child Neurology; receives royalties for the publication of Nelson's Textbook of Pediatrics and Swaiman's Pediatric Neurology: Principles and Practice and is funded by the NIH.Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Heilman serves as an editorial board member for ACTA Neuropsychologia, The Journal of Contemporary Neurology, Journal of the International Neuropsychological, Neurocase, Neuropsychiatry, Neuropsychology and Behavioral Neurology-Cognitive and Behavioral Neurology, Brain and Cognition, Journal of Neuropsychology and Journal of Clinical Neurology; receives royalties for the publication of Clinical Neuropsychology, fifth edition, PGY1: Lessons in Caring, Neurological Therapeutics : Principles and Practice second edition, Creativity and the Brain, Clinical Neuropsychology, fourth edition, Neurological Therapeutics : Principles and Practice, The Matter of Mind, A Neurologist's View of Brain Behavior Relationships, Apraxia, Helping People with Memory Disorders: A Guide for You and Your Family, Clinical Neuropsychology, third edition, Clinical Neuropsychology, second edition, Neuropsychology of Human Emotion, Clinical Neuropsychology and The Differential Diagnosis of Neurological Diseases; and receives funding from current (active) funded research proposals, Alzheimer's Disease Initiative State of Florida, Dept. of Elder Affairs, Memory Disorder Clinics, and the NIH.

1) Antiplatelets versus anticoagulation and 2) Topic of the month: Apraxias. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Hugh Markus about his paper on antiplatelets versus anticoagulation for dissection. Dr. Chafic Karam is reading our e-Pearl of the week about caffeine and Parkinson disease. In the next part of the podcast Dr. Ted Burns interviews Dr. Ken Heilman about limb-kinetic, ideomotor and ideational apraxias and how it might come to our attention. The participants had nothing to disclose except Drs. Markus, Karam, Burns and Heilman.Dr. Markus has served on scientific advisory boards for W. L. Gore & Associates, Inc., Boehringer Ingelheim, and Sanofi-Synthélabo; serves on the editorial boards of Stroke and Clinical Neurology and Neurosurgery; receives publishing royalties for Stroke Medicine (Oxford University Press, 2010); served as a consultant for Archimex SAS and Shire plc; and has received research support from Archimex SAS, Shire plc, MRC UK, the Stroke Association, the European Union, Wellcome Trust and the British heart Foundation.Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Heilman serves as an editorial board member for ACTA Neuropsychologia, The Journal of Contemporary Neurology, Journal of the International Neuropsychological, Neurocase, Neuropsychiatry, Neuropsychology and Behavioral Neurology-Cognitive and Behavioral Neurology, Brain and Cognition, Journal of Neuropsychology and Journal of Clinical Neurology; receives royalties for the publication of Clinical Neuropsychology, fifth edition, PGY1: Lessons in Caring, Neurological Therapeutics : Principles and Practice second edition, Creativity and the Brain, Clinical Neuropsychology, fourth edition, Neurological Therapeutics : Principles and Practice, The Matter of Mind, A Neurologist's View of Brain Behavior Relationships, Apraxia, Helping People with Memory Disorders: A Guide for You and Your Family, Clinical Neuropsychology, third edition, Clinical Neuropsychology, second edition, Neuropsychology of Human Emotion, Clinical Neuropsychology and The Differential Diagnosis of Neurological Diseases; and receives funding from current (active) funded research proposals, Alzheimer's Disease Initiative State of Florida, Dept. of Elder Affairs, Memory Disorder Clinics, and the NIH.

1) Creutzfeldt-Jakob disease and 2) Topic of the month: Apraxias. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Clive Hamlin about his paper on diagnosis of Creutzfeldt-Jakob disease. Dr. Chafic Karam is reading our e-Pearl of the week about POEMS syndrome. In the next part of the podcast Dr. Ted Burns interviews Dr. Ken Heilman about definitions for apraxia and various forms of apraxia. Dr. Burns will interview Dr. Heilman about other forms of apraxias over the next three weeks. The participants had nothing to disclose except Drs. Burns, Karam, and Heilman.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Heilman serves as an editorial board member for ACTA Neuropsychologia, The Journal of Contemporary Neurology, Journal of the International Neuropsychological, Neurocase, Neuropsychiatry, Neuropsychology and Behavioral Neurology-Cognitive and Behavioral Neurology, Brain and Cognition, Journal of Neuropsychology and Journal of Clinical Neurology; receives royalties for the publication of Clinical Neuropsychology, fifth edition, PGY1: Lessons in Caring, Neurological Therapeutics : Principles and Practice second edition, Creativity and the Brain, Clinical Neuropsychology, fourth edition, Neurological Therapeutics : Principles and Practice, The Matter of Mind, A Neurologist's View of Brain Behavior Relationships, Apraxia, Helping People with Memory Disorders: A Guide for You and Your Family, Clinical Neuropsychology, third edition, Clinical Neuropsychology, second edition, Neuropsychology of Human Emotion, Clinical Neuropsychology and The Differential Diagnosis of Neurological Diseases; and receives funding from current (active) funded research proposals, Alzheimer's Disease Initiative State of Florida, Dept. of Elder Affairs, Memory Disorder Clinics, and the NIH.

In this special podcast for the Neurology Journal, Dr. Ted M. Burns plays a dozen of the many interesting audio clips from Neurology Podcasts of the 2011-2012 academic year.

1) Prevention of new brain lesions and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Pearce Korb interviews Dr. David Mohr about his paper on stress management for the prevention of new brain lesions. Dr. Jennifer Fugate is reading our e-Pearl of the week about Panayiotopoulos syndrome. In the next part of the podcast Dr. Alberto Espay interviews Dr. Chris Austin about his plenary session on translational therapeutics development at NIH. The participants had nothing to disclose except Drs. Mohr, Fugate, and Espay.Dr. Mohr is a consultant for the NIH and receives research support from NIH.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay Pharmaceuticals, Inc., Abbott, Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Solstice Neurosciences, and Eli Lilly and Company; and honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society. He serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders.

1) Stroke thrombolysis and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Atte Meretoja about her paper on reducing in-hospital delay. Dr. Jennifer Fugate is reading our e-Pearl of the week about mytonic dystrophy. In the next part of the podcast Dr. Alberto Espay interviews Dr. Reisa Sperling about her plenary session on molecular and functional imaging detection of preclinical Alzheimer disease. The participants had nothing to disclose except Drs. Meretoja, Fugate, Espay and Sperling.Dr. Meretoja has served as a consultant for Boehringer Ingelheim, and has received honoraria from Boehringer Ingelheim for speaking at educational symposia, travel expenses from H Lundbeck A/S, and research support from Sigrid Juselius Foundation, Biomedicum Helsinki Foundation, Instrumentarium Science Foundation, Yrjo Jahnsson Foundation, Paivikki and Sakari Sohlberg Foundation, Maire Taponen Foundation, Finnish-Norwegian Medical Foundation and Emil Aaltonen Foundation.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay Pharmaceuticals, Inc., Abbott, Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Solstice Neurosciences, and Eli Lilly and Company; and honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society. He serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders.Dr. Sperling received a speaker honorarium from Pfizer Inc.; serves on the editorial board of Alzheimer¹s disease and Associated Disorders; has served as a consultant for Roche, Janssen, Pfizer Inc, Bayer Schering Pharma, Eisai Inc., Satori, Kyowa Hakko Kirin, Bristol-Myers Squibb and Avid Radiopharmaceuticals, (unpaid); has received research support from Janssen, and Bristol-Myers Squibb, NIH/NIA, Alzheimer¹s Association, American Health Assistance Foundation, and an Anonymous Foundation.

1) Anterior disconnection syndrome and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Waugh interviews Drs. Ana Pereira and Alvardo Pascual-Leone about their paper on the anterior disconnection syndrome. Dr. Jennifer Fugate is reading our e-Pearl of the week about normal pressure hydrocephalus. In the next part of the podcast Dr. Alberto Espay interviews Dr. Richard Bedlack about his plenary session on contemporary clinical issues. The participants had nothing to disclose except Drs. Waugh, Pascual-Leone, Fugate, Espay and Bedlack.Dr. Waugh serves as an editorial board member of the Journal of Pediatric Biochemistry.Dr. Pascual-Leone serves on the scientific advisory board for Nexstim, NeoSync, Starlab, Neuronix, Allied minds and NovaVision, inc.; serves as an Associate Editor for European Journal of Neuroscience and Frontiers in Neuroscience; is listed as co-inventor in several patents related to real-time integration of TMS with EEG and functional imaging; receives research support from Nexstim, Neuronix, NIH, The Michael J. Fox Foundation, Berenson-Allen Foundation and RJG Family Foundation.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay Pharmaceuticals, Inc., Abbott, Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Solstice Neurosciences, and Eli Lilly and Company; and honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society. He serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders.Dr. Bedlack serves on the scientific advisory board DSMB for the ceftriaxone ALS trial; serves on the speakers' bureau of Pfizer Inc, Eli Lilly and Company, Athena Diagnostics and Avanir Pharmaceuticals; is a consultant for Avanir Pharmaceuticals, Sanofi-aventis, Athena Diagnostics and UCB; receives research support from UCB, Biogen, Cytokinetics, Neuraltis and NIH. His clinic is sponsored by the ALS Association; and he is also involved in conducting clinical trials.

1) Patients treated with antiepileptic drugs and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Dr. John Wark and Prof. Terry O' Brien about their paper on falls and fractures in patients treated with antiepileptic drugs. Dr. Jennifer Fugate is reading our e-Pearl of the week about Duchenne muscular dystrophy. In the next part of the podcast Dr. Alberto Espay continues his interview with Drs. Titulaer and Vincent about their lecture on clinical features, treatment and outcome of 500 patients with anti-NMDA receptor encephalitis. Next week, we will continue with interviews from other plenary sessions. All participants have disclosures.Dr. Fountain serves as an editorial board member of Epilepsy Currents, serves on the Board of Directors, National Association of Epilepsy Centers, receives travel reimbursement from UCB; performs EEG interpretation for the University of Virginia (10% effort); receives research support from UCB, Sepracor Inc., Medtronic, Inc., Vertex Pharmaceuticals and NeuroPace; and is funded by the NIH.Dr. Wark serves on the scientific advisory boards for Amgen/GlaxoSmithKline, Novartis and LactoPharma; serves as a specialist editor of Clinical Science; editorial board members of Osteoporosis International and Journal of Osteoporosis; serves on the speakers' bureau of Servier, Amgen, Novartis, Sanofi-aventis, Eli Lilly and Company, Merck Serono, Sharp Dohme Company; serves on the speakers' bureau of Servier, Amgen, Novartis, Amgen, Novartis, Sanofi-aventis, Eli Lilly and Company, Merck Serono, Sharp Dohme Company; received travel reimbursement from Servier; is a consultant for Vactec and AstraZeneca; performs bone density testing for the Royal Melbourne Hospital (10% effort); receives royalties from the publication of the book Physical Activity and Bone Health; receives research support from Novartis, UCB, Sanofi-aventis, Eli Lilly and Company, Monash University, LaTrobe University, National Health and Medical Research Council of Australia, Victorian Cancer Agency and ANZ Trustees.Prof. O'Brien served as editorial board members of Epilepsia, Journal of Clinical Neuroscience and Epilepsy and Behavior; serves on the speakers' bureaus of UCB, Sanofi-aventis and SiGen and receives research support from UCB, Sanofi-aventis Jansen-Cilag, Royal Melbourne Hospital Neuroscience Foundation and Epilepsy Research Foundation and is funded by the NIH and NHMRC.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay Pharmaceuticals, Inc., Abbott, Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Solstice Neurosciences, and Eli Lilly and Company; and honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society. He serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders.Dr. Titulaer received research support from a KWF fellowship of the Dutch Cancer Society.Dr. Vincent served on the scientific advisory board for Patrick Berthoud Trust as Chair and member of the MGFA SAB; received honoraria from Baxter International; serves as Associate Editor for Brain; is a consultant for Athena Diagnostics; receives royalties from the publications of Clinical Neuroimmunology Blackwells Dale and Vincent Inflammatory and Autoimmune Disorders of the Nervous System in Children Mac Keith Press; receives revenue from Athena Diagnostics and RSR Ltd for MuSK antibodies for a patent, holds a patent for CASPR2, Lgi1, Contactin2 antibodies; receives research support from NIH, EU network grant, Euroimmun AG and Sir Halley Stewart Trust; performs neuroimmunology service for her department and is associated with Myasthenia Gravis Foundation of America.

1) Bleeding risk after stroke thrombolysis and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Michael Knoflach about his paper on an increased bleeding risk after stroke thrombolysis. Dr. Jennifer Fugate is reading our e-Pearl of the week about hummingbird sign in PSP. In the next part of the podcast Dr. Alberto Espay interviews Drs. Titulaer and Vincent about their lecture on clinical features, treatment and outcome of 500 patients with anti-NMDA receptor encephalitis. Next week, we will continue with our interview with Drs. Titulaer and Vincent. The participants had nothing to disclose except Drs. Kissela, Kiechl, Fugate, Espay and Mehler.Dr. Kissela serves on scientific advisory boards for Northstar Neuroscience and Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from NexStim and the NIH, and provides medico-legal reviews.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay Pharmaceuticals, Inc., Abbott, Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Solstice Neurosciences, and Eli Lilly and Company; and honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society. He serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders.Dr. Titulaer received research support from a KWF fellowship of the Dutch Cancer Society.Dr. Vincent served on the scientific advisory board for Patrick Berthoud Trust as Chair and member of the MGFA SAB; received honoraria from Baxter International; serves as Associate Editor for Brain; is a consultant for Athena Diagnostics; receives royalties from the publications of Clinical Neuroimmunology Blackwells Dale and Vincent Inflammatory and Autoimmune Disorders of the Nervous System in Children Mac Keith Press; receives revenue from Athena Diagnostics and RSR Ltd for MuSK antibodies for a patent, holds a patent for CASPR2, Lgi1, Contactin2 antibodies; receives research support from NIH, EU network grant, Euroimmun AG and Sir Halley Stewart Trust; performs neuroimmunology service for her department and is associated with Myasthenia Gravis Foundation of America.

Vitamins & Neurology